转移性去势抵抗性前列腺癌患者中PARP1上调是否与PSMA表达相关:基于[18F]PARPi与[68Ga]PSMA PET/CT的研究
该回顾性研究对22例转移性去势抵抗性前列腺癌(mCRPC)患者的[18F]PARPi与[68Ga]Ga-PSMA-11 PET/CT进行定量分析,骨转移灶占多数(n=57),PARPi SUVmax均值4.9±1.5、PSMA SUVmax均值30.9±28.3。骨转移灶PARPi与PSMA摄取在SUVmean、SUVpeak、SUVmax均呈显著相关(r=0.43–0.48,p<0.001),骨外病灶SUVpeak亦相关(r=0.49,p=0.04)。有无同源重组缺陷(HRD)改变的患者间PARPi摄取无显著差异(均p>0.05)。作者认为[18F]PARPi有作为mCRPC诊断影像工具的潜力,但需更多研究评估其临床获益。
要点
- 22例mCRPC患者行[18F]PARPi与[68Ga]PSMA-11 PET/CT,骨转移灶57个,PARPi SUVmax均值4.9±1.5,PSMA SUVmax均值30.9±28.3。
- 骨转移灶PARPi与PSMA摄取显著相关:SUVmean r=0.48、SUVpeak r=0.48、SUVmax r=0.43,均p<0.001。
- 有无HRD改变的患者间PARPi摄取无显著差异(均p>0.05)。
核心结论
- mCRPC患者中[18F]PARPi摄取可观,且PARPi摄取与PSMA表达存在相关性,提示[18F]PARPi有作为mCRPC诊断影像工具的潜力。
- 作者指出需更多研究评估这一新型放射性示踪剂的临床获益。
研究设计与样本
- 回顾性定量分析22例男性mCRPC患者,均行[18F]PARPi与[68Ga]Ga-PSMA-11 PET/CT。
- 勾画PARPi摄取高于背景的病灶,以标准化摄取值(SUV)与其[68Ga]PSMA摄取进行相关分析,并比较HRD改变对PARPi肿瘤摄取的影响。
主要发现
- PARPi摄取的转移灶多数位于骨(n=57),PARPi SUVmax均值4.9±1.5,[68Ga]PSMA SUVmax均值30.9±28.3。
- 另检出3个前列腺局部病灶、14个淋巴结和4个其他转移灶。
- 骨转移灶PARPi与[68Ga]PSMA摄取显著相关:SUVmean r=0.48(p<0.001)、SUVpeak r=0.48(p<0.001)、SUVmax r=0.43(p<0.001)。
- 骨外病灶PARPi与[68Ga]PSMA的SUVpeak显著相关(r=0.49,p=0.04)。
- 有无HRD改变的患者转移灶PARPi摄取无显著差异(均p>0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者指出需更多研究评估这一新型放射性示踪剂的临床获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: [18F] Poly-ADP-ribose polymerase inhibitors (PARPi), a novel radiotracer, enables visualization of PARP1 upregulation by PET imaging. Here, we aimed to quantify PARPi uptake in tumor lesions of metastatic castration-resistant PCa (mCRPC) patients and perform a comparison with prostate specific membrane antigen (PSMA) expression using PET/CT scans. METHODS: Data from 22 male patients with mCRPC, who underwent [18F]PARPi and [68Ga]Ga-PSMA-11 PET/CT scans, were retrospectively quantified. Lesions with relevant PARPi uptake (higher than background) were delineated and correlated with their [68Ga]PSMA uptake using standardized uptake values (SUV). Additionally, a comparison was performed to investigate the effects of homologous recombination deficiency (HRD) alterations on PARPi tumor uptake. RESULTS: The majority of metastatic PCa lesions that exhibited PARPi uptake were located in the bones (n = 57), with mean SUVmax values of 4.9 ± 1.5 for PARPi and 30.9 ± 28.3 for [68Ga]PSMA. Additionally, 3 local prostate lesions, 14 lymph nodes and 4 further metastatic lesions were detected. Significant correlations were identified between PARPi- and [68Ga]PSMA uptake, as measured by SUVmean (r = 0.48, p < 0.001), SUVpeak (r = 0.48, p < 0.001) and SUVmax (r = 0.43, p < 0.001) of the osseous metastatic lesions and SUVpeak (r = 0.49, p = 0.04) of extraosseous lesions. No significant differences were found between PARPi uptake of metastatic lesions in patients with or without HRD alterations (all p > 0.05). CONCLUSION: Results showed a considerable uptake of [18F]PARPi in mCRPC patients and indicated a correlation between PARPi uptake and PSMA expression, suggesting the potential of using [18F]PARPi as a diagnostic imaging tool in mCRPC patients. More studies are needed to evaluate the clinical benefit of this innovative radiotracer.
引用
- Einspieler H, Ofner H, Ozenil M, et al. Does PARP1 up-regulation correlate with PSMA expression in patients with metastatic castration-resistant prostate cancer studied with [18F]PARPi and [68Ga]PSMA PET/CT? Eur J Nucl Med Mol Imaging. 2025. PMID: 40682676. doi:10.1007/s00259-025-07448-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。